Trioar
PrivateLast Round
Series C
Oct 22, 2026
Est. Valuation
$56.9M
Total Funding Raised
$77.84M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Trioar is a biotechnology company that develops next-generation antibody-based therapeutics, including antibody-drug conjugates (ADCs) and immuno-oncology treatments, using its proprietary TROCAD™ and TROSIG™ platform technologies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Trioar Comparables
Compare Trioar with similar companies based on industry and business-model similarity.
Trioar Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Oct 22, 2026 | ||||
| Grant | Jul 6, 2026 | ||||
| Series B | Aug 28, 2025 | ||||
| Series B | Jul 17, 2025 | ||||
| Series A | May 24, 2023 | ||||
Pre Seed | Feb 24, 2022 |
Trioar Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CKD Venture Capital | Series B |
| Shinhan Venture Investment | Series B |
| KB Investment | Series B, Pre Seed, Series A |
| DS Asset Management | Series C |
| Woori Venture Partners Co., Ltd. | Series C, Series B |
| SAGE ONE PARTNERS | Series C |
| Kiwoom Investment | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 22, 2026
$25M round led by Korea Development Bank.
- May 24, 2023
$9.2M round led by LSK Investment
Trioar Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Trioar's valuation, stock price, and market status.
Is Trioar a public or private company?
Trioar is a private company.
What is the current stock price of Trioar?
Trioar is a private company, so its shares have no public market price. Caplight tracks Trioar's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Trioar worth (valuation)?
Trioar's valuation is estimated at $56.9M based on funding round data.
Can I buy Trioar stock?
Trioar shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Trioar's last funding round?
Trioar's most recent funding round was Series C on October 22, 2026.
Who are the main investors in Trioar?
Key investors in Trioar include Woori Venture Partners Co., Ltd., LSK Investment, Korea Development Bank, LSK Investment, Woori Venture Partners.
Will Trioar IPO soon?
No public IPO plans have been announced for Trioar.
How can I track Trioar secondary market activity?
Caplight tracks bids, offers, and trades in Trioar's shares on secondary markets.